Study Shows Promise of New Anti|KRAS Drug for Pancreatic Cancer

UCSF Pancreatic Cancer Clinical Trials — San Francisco Bay Area

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, ...

Sotorasib Reveals Anti-Tumor Efficacy in KRAS G12C-Positive ...

New results from the advanced pancreatic cancer cohort of the CodeBreaK 100 trial show positive efficacy and safety. ... KRAS inhibition with ...

Immunotherapy for Pancreatic Cancer

Pancreatic cancer has few treatment options. Immunotherapy for pancreatic cancer research is vital to providing patients with new hope.

New MD Anderson Research Uncovers Drug Combo That Could ...

The preclinical studies showed that combining immunotherapy with a KRAS inhibitor can lead to long-lasting tumor elimination in pancreatic ...

Pancreatic Cancer: The Search for an Achilles Heel | AACR | Blog

Currently, FDA-approved inhibitors only exist for one KRAS mutation, G12C, which is prevalent in lung and colorectal cancer but only accounts ...

Existing drug shows promise targeting common cancer mutation

To test it out, the researchers pitted it against tumors grown in the lab from five pancreatic cancer patients. A7519 successfully suppressed ...

New vaccine shows promise at preventing pancreatic cancer ...

This trial tested a vaccine in a small group of cancer patients, including 20 with pancreatic cancer, who had faults in KRAS and were also found to have tumour ...

Revolution Medicines' RAS inhibitor shows promise in early-stage ...

Revolution Medicines' experimental drug staved off cancer progression for seven and a half months in second-line metastatic pancreatic cancer patients.

Consensus, debate, and prospective on pancreatic cancer treatments

Targeted therapies represented by PARP and KRAS inhibitors are also under investigation, showing benefits in improving progression-free survival ...

The Promising Pancreatic Cancer Vaccine Clinical Trial - UC Health

The promising new mRNA vaccine trial offers a significant breakthrough in pancreatic cancer treatment, showing hope against the highest ...

Clinical immunotherapy in pancreatic cancer

In contrast to the combination of anti-CTLA-4 with gemcitabine, the addition of PD-1 and CTLA-4 antibodies to chemotherapy has shown better ...

Discovery unveils promising anticancer drug targeting KRAS protein

They demonstrated that KRB-456 significantly inhibits the growth in mice of mutant KRAS-addicted tumors derived from pancreatic cancer patients ...

Barriers and opportunities in pancreatic cancer immunotherapy

Treatment with a FAK inhibitor led to a reduction in fibrosis and tumor-associated immunosuppressive cells, sensitizing the p48-Cre;LSL-KrasG12D ...

Immunotherapy for pancreatic cancer boosts survival more than 75 ...

A new study has found that a certain type of immunotherapy — even when used without chemotherapy or radiation — can boost survival from the ...

New alliances to increase the odds in pancreatic cancer survival

PDAC patients with KRASG12C mutations showed modest activity with objective response rates ranging from 21.1% to 50%, respectively [27], [28]. Since KRASG12C ...

One-two punch: Novel drug pairing could beat pancreatic cancer

Mouse pancreatic tumors were significantly smaller after being treated with a combination of KRAS inhibitor MRTX1133 and ERBB inhibitor Afatinib.

New Drug Pairing for Pancreatic Cancer Shows Promise in Lab ...

The study was the first to confirm that human pancreatic cells treated with the KRAS inhibitor MRTX1133 (Mirati Therapeutics) do indeed ...

Pancreatic Cancer Vaccine Shows Promise in Small Trial

Using mRNA tailored to each patient's tumor, the vaccine may have staved off the return of one of the deadliest forms of cancer in half of ...

FibroGen Announces Topline Results from Two Late-Stage ...

Pamrevlumab is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer ( ...

UC-developed drug shows promise in preventing pancreatic cancer ...

The University of Cincinnati Cancer Center's Vladimir Bogdanov found a new drug developed in his lab was effective at preventing pancreatic ...